跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈

Elsevier
通过我们出版

欢迎访问 Elsevier Connect

研究、医疗和技术社区的新闻、信息和专题。

Students sitting around a table at library

焦点专题

The future we build could depend on research we don’t read

Policy is meant to be shaped by evidence. But what happens when the most relevant research never reaches decision-makers?

New research supported by Elsevier datasets suggests that roughly two-thirds of highly policy-relevant science may go uncited — not because it lacks quality, but because it remains invisible. As AI becomes part of how evidence is found and synthesized, trusted sources, transparency and broader visibility are becoming essential to better decisions.

What if the next life-saving drug is buried in a patent diagram?

In drug discovery, the evidence researchers need often already exists — scattered across journals, patents, figures and chemical diagrams that conventional search may miss.

AI-supported workflows grounded in trusted scientific knowledge are helping researchers connect chemistry, bioactivity and patent evidence faster, with insights traceable back to their sources. From surfacing hidden chemistry in images to exploring millions of drug–disease connections at scale, better access to quality information can help teams move from search to decision with greater confidence.